Terns sold to Merck for 13% lower than pharma's initial offer because of clinical data
Terns sold to Merck for 13% lower than pharma's initial offer because of clinical data
Body unavailable. Use the original source.
Terns sold to Merck for 13% lower than pharma's initial offer because of clinical data
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.